Treatment Experienced Hiv 1 Infection With Resistance Therapeutics
1. Fuzeon patent expiration
Treatment: Treatment of hiv
FUZEON IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6133418 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Nov, 2014
(11 years ago) | |
| US6475491 | ROCHE | Treatment of HIV and other viral infections using combinatorial therapy |
Jun, 2015
(10 years ago) | |
| US5464933 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Jun, 2013
(12 years ago) | |
Drugs and Companies using ENFUVIRTIDE ingredient
Market Authorisation Date: 13 March, 2003
Dosage: INJECTABLE
More Information on Dosage
FUZEON family patents
2. Intelence patent expiration
Treatment: Treatment of hiv infection in combination with one or more additional hiv antiviral agents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7887845 | JANSSEN R AND D | Antiviral compositions |
Mar, 2019
(6 years ago) | |
|
US6878717 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
| US6878717 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US8003789 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(6 years ago) | |
| US7037917 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Dec, 2020
(5 years ago) | |
|
US7037917 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Jun, 2021
(4 years ago) | |
|
US8003789 (Pediatric) | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
May, 2020
(5 years ago) | |
|
US7887845 (Pediatric) | JANSSEN R AND D | Antiviral compositions |
Sep, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2013 |
| New Patient Population(NPP) | Mar 26, 2015 |
| Pediatric Exclusivity(PED) | Jan 16, 2022 |
Drugs and Companies using ETRAVIRINE ingredient
NCE-1 date: 16 January, 2021
Market Authorisation Date: 26 March, 2012
Dosage: TABLET
More Information on Dosage
INTELENCE family patents